Clinical Trial Update: Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituximab in combination with the DexaBEAM salvage regimen for relapsed non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Carmustine (carmustine)
• DEXAMETHASONE (Dexamethasone)
• Etoposide (Etoposide)
• Melphalan (Melphalan)
• Rituximab (rituximab)

Snippet

Sponsor: Georg Hess, MD | Conditions: Relapsed Non-Hodgkin-Lymphoma | Phase 2 | Status: COMPLETED